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The accurate identification of Salmonella enterica subsp. enterica serovar Typhi variants that fail to express
the capsular polysaccharide, Vi, is an important and much discussed issue for medical microbiology. We have
tested a multiplex PCR method which shows the presence or absence of the genetic locus required for Vi
expression. Of 2,222 Salmonella serovar Typhi clinical isolates collected from patients’ blood over a 4-year
period in a region of Pakistan where typhoid is endemic, 12 tested negative for Vi expression by serological
agglutination. However, only 1 of these 12 was Vi negative by the multiplex PCR method. This result was
confirmed by immunofluorescence, the most sensitive method for Vi characterization in Salmonella serovar
Typhi. The multiplex PCR described therefore represents a simple and accurate method for surveillance for
Vi-negative variants of Salmonella serovar Typhi in Pakistan. Testing of clinical isolates of Salmonella serovar
Typhi, before subculture, from other regions where Vi-negative Salmonella serovar Typhi has been described
should be carried out so that the impact of vaccination with purified Vi antigen on the levels of Vi-negative
Salmonella serovar Typhi in bacterial populations can be assessed.
The causative organism of human typhoid fever, Salmonella
enterica subsp. enterica serovar Typhi, unlike most of the other
serovars of Salmonella, expresses a capsular polysaccharide
antigen known as Vi. In vitro studies have shown that Vi is
antiopsonic and antiphagocytic (20), reduces the level of se-
cretion of Salmonella serovar Typhi-induced tumor necrosis
factor alpha (a marker of activation) by human macrophages
(10), and increases the level of resistance of the organism to
oxidative killing (20). The presence of the Vi antigen also
increases the infectivity (11) of Salmonella serovar Typhi and
the severity of disease (13) in volunteers. The Vi capsule is,
however, not essential for infection, as Vi-negative mutants of
Salmonella serovar Typhi are able to establish infection and
cause a typhoid fever-like illness in human volunteers (11, 13).
Furthermore, there have been reports of outbreaks of typhoid
fever caused by Vi-negative Salmonella serovar Typhi (5).
The reliance of serological (agglutination) testing for Vi
expression has some limitations. The level of Vi expression on
Salmonella serovar Typhi varies in response to changes in cul-
ture conditions and is associated with regulation by the OmpR
and EnvZ two-component regulatory system, which is influ-
enced by factors such as osmolarity (26). Also, Vi-negative
mutants of Salmonella serovar Typhi are known to accumulate
from previously Vi-positive Salmonella serovar Typhi isolates
following laboratory passage. Fortunately, the genetic control
of Vi expression is now relatively well understood, and so
determination of the genetic conformation of truly Vi-negative
Salmonella serovar Typhi is now possible. The Vi biosynthetic
and export proteins are encoded within the viaB locus (9), a
region of DNA located within the acquired DNA island known
as Salmonella pathogenicity island 7 (SPI-7) (25, 27). Insertion
and deletion mutations in the tviA gene, encoded within the
viaB locus, that can lead to the loss of Vi expression and an
increase in invasive properties have been reported (30). Fur-
thermore, spontaneous loss of the whole of SPI-7 in Vi-nega-
tive mutants has been reported in stored isolates (23), and
precise excision of SPI-7 has been demonstrated (6). Thus, Vi
antigen expression is encoded on an unstable and possibly
mobile region of the Salmonella serovar Typhi genome, which
has been well described (27).
An effective vaccine based on purified Vi antigen has been
developed and licensed for use as a parenteral vaccine against
typhoid fever in humans. A single dose of the antigen induces
a protective immune response against Salmonella serovar
Typhi in adults and older children (7), and when it is conju-
gated to a protein carrier the vaccine is also effective in young
children (19). Purified Vi antigen has been used in regions
where typhoid is endemic (1, 5, 18), and there is a long-running
debate concerning its efficacy in the presence of Vi-negative
isolates (3, 4, 16, 22, 28). Experience with Streptococcus pneu-
moniae vaccines based on combination capsular antigens has
indicated that the immunization of populations with such vac-
cines may favor the emergence of capsular types not present in
the vaccine (21, 24). There is potential selective pressure in
favor of Vi-negative Salmonella serovar Typhi from the ex-
tended use of Vi-based vaccines, and there is a paucity of
surveillance data based on molecular biology-based tests. We
have therefore developed and characterized tools which allow
us to monitor the prevalence of Vi-negative Salmonella serovar
Typhi in regions where the Vi vaccine is being introduced.
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Here we show that Vi-negative Salmonella serovar Typhi was
very rare in a region of Pakistan where typhoid was highly
endemic before vaccination with purified Vi antigen was intro-
duced.
MATERIALS AND METHODS
Bacterial isolates. All Salmonella serovar Typhi isolates investigated were
isolated from blood in the Microbiology Laboratory of the Aga Khan University,
Karachi, Pakistan, between 1999 and 2002. Control strains SARB63 and
SARB64 (Salmonella Reference Collection, Calgary, Alberta, Canada), CT18
(25), and Ty2 (a gift from M. Popoff, Pasteur Institute, Paris, France) were used
as negative and positive controls, as described for each method. Primary isolation
of the organism from blood was carried out with commercial blood culture
bottles (BACTEC 9240; Becton Dickinson, Oxford, United Kingdom) and a
single round of growth on sheep blood agar (Oxoid, Basingstoke, United King-
dom). Identification and Vi agglutination (Murex, Dartford, United Kingdom)
were carried out with isolates obtained directly from the blood agar. Isolates
were identified as Salmonella serovar Typhi by identification of the following
characteristics: glucose positive without gas formation, lactose negative and H2S
positive on a Kliglar iron agar slant (Oxoid), citrate (Oxoid) negative, indole
(Oxoid) negative, and positive serology with both O9 and Hd antigens (Murex,
Dartford, United Kingdom). If an isolate was Vi positive but negative for O9, the
organism was boiled for 10 min and the agglutination test was repeated. Agglu-
tination was carried out according to the instructions of the manufacturer. API
20E strips (bioMe´rieux, Basingstoke, United Kingdom) and DNA sequencing of
a variable region (the phoN-pheU intergenic region) and a conserved region
(aroC) of the genome were used to confirm the identities of unusual organisms.
PCR amplification for presence of Vi genes. A multiplex PCR was developed
to detect the deletion of the genes encoding Vi, including tviB. Three sets of
primers were designed (Table 1) to specifically amplify (i) an internal region of
the tviB gene in the viaB locus, a gene essential for the production of Vi capsular
antigen (primers tviB-F and tviB-R); (ii) an intergenic region of 1,275 bp between
the pheU (phenylalanine tRNA) and phoN genes, which produces a product only
in the absence of SPI-7 (primers DE0032-F and DE0083-R); and (iii) a chro-
mosomal gene, aroC, which acts as an internal PCR control (primers aroC-F and
aroC-R) (Fig. 1). PCRs were performed with an Expand High Fidelity PCR kit
(Roche, Basel, Switzerland). Each reaction mixture contained 300 nM primer,
100 ng of DNA template, 200 M deoxynucleoside triphosphates, and 2.6 U of
Taq polymerase in a total volume of 50 l of reaction buffer. PCR conditions
were 95.0°C for 3 min, followed by 28 cycles of 95.0°C for 30 s, 57.0°C for 1 min,
and 72.0°C for 3 min. The PCR products were visualized by ethidium bromide
staining after electrophoresis on a 1% agarose gel.
Sequencing of aroC and tRNA PCR products. The PCR products were purified
with DNA purification kits (Qiagen, Crawley, United Kingdom). Sequencing of
the products obtained with the specific primers was performed with BigDye
Chain Terminators on an ABI 3700 capillary machine. The sequence was edited
and aligned by using Bioedit software (http://www.mbio.ncsu.edu/BioEdit
/bioedit.html). It is known that the aroC sequence varies among S. enterica
isolates and is conserved within particular Salmonella serotypes (17). Conse-
quently, the precise DNA sequence of aroC provides an accurate signature of a
particular S. enterica serovar, and so this approach was used to independently
confirm the identities of selected isolates. Experience with the intergenic region
phoN to pheU of different Salmonella serovars (27) and aroC of Salmonella
serovar Typhi (17) allowed us to use sequence data from these regions to support
the identification.
FIG. 1. Schematic representation of the multiplex PCR for the detection of SPI-7 and tviB.
TABLE 1. Primers used in the multiplex PCR for detection of tviB and SPI-7 in Vi agglutination-negative Salmonella isolates
Interpretation if band detected Primer Sequence Positive controlstrain(s)
Product size (bp [gene
amplified])




SPI-7 absent DE0032-F 5-GCTCAGTCGGTAGAGCAGGGGATT-3 SARB 64 1,275 (tRNA-phoN)
DE0083-R 5-TCATCTTCAGGACGGCAGGTAGAATG-3
Salmonella DNA present aroC-F 5-GGCACCAGTATTGGCCTGCT-3 CT18 639 (aroC)
aroC-R 5-CATATGCGCCACAATGTGTTG-3
VOL. 43, 2005 Vi-NEGATIVE SALMONELLA SEROVAR TYPHI 1159
Immunofluorescence detection of Vi. All clinical isolates which were Vi neg-
ative by agglutination were investigated for Vi expression by immunofluores-
cence. Bacteria were grown at 37°C in Luria-Bertani (LB) broth (0.17 M NaCl)
for 8 h with aeration, subcultured at a 1/100 dilution into fresh LB broth (0.17 M
NaCl), and cultured for a further 16 h at 37°C without aeration. Bacteria from
500 l of culture were harvested by centrifugation in a benchtop microcentrifuge
(Eppendorf 5415D) (13,000 rpm, 2 min) and resuspended in 500 l of phos-
phate-buffered saline (PBS). The bacteria were diluted 1/100 in PBS, and a 50-l
drop was placed in the wells of a glass chamber slide (Falcon, Poole, United
Kingdom). The slides were incubated at room temperature for 30 min. Excess
bacteria and PBS were removed, and the slides were fixed in 4% paraformalde-
hyde in PBS for 30 min at room temperature. The slides were washed twice with
PBS and then placed in PBS containing 20 mM ammonium chloride and stored
at 4°C until they were used. Before the slides were stained, they were washed
twice with PBS. Primary antibodies (goat anti-Salmonella antibody and rabbit
anti-Vi antibody; Murex) diluted 1/200 in PBS containing 10% horse serum were
applied to the bacteria (40 l per well) for 30 min at room temperature in a
humid atmosphere. The slides were washed twice in PBS, and secondary anti-
bodies (donkey anti-goat antibody conjugated to Cy2 and donkey anti-rabbit
antibody conjugated to Rhodamine Redex, diluted 1/200 and 1/400, respectively)
in PBS containing 10% horse serum were applied to the bacteria (40 l per well)
for 30 min at room temperature in a humid atmosphere. The slides were washed
twice in PBS and once in water, dried, and mounted. The bacteria were visualized
by epifluorescence microscopy. The bacteria were visible on the green channel,
and the Vi antigen was visible on the red channel.
RESULTS
Vi agglutination. In the routine diagnostic laboratory at the
Aga Khan University during the period of study (1999 to 2002),
2,227 bacterial blood isolates were provisionally identified as
Salmonella serovar Typhi on the basis of biochemistry test
results and agglutination with O9 and Hd antisera. Of these,
2,210 (99.2%) isolates gave positive results for Vi by aggluti-
nation carried out at the same time as the identification tests.
The 17 Vi agglutination-negative putative Salmonella serovar
Typhi isolates identified from direct culture in this screening
were subjected to a more detailed analysis after storage. Of
these original 17 isolates, 5 were not Salmonella serovar Typhi.
Three were positive for O9 but negative for Hd, which led to
their classification as group D salmonellae but not Salmonella
serovar Typhi. Interestingly these isolates gave a false-positive
result for Hd agglutination when they tested by the slide ag-
glutination format and were negative for citrate utilization
when they were tested with 2.5 ml of citrate agar. Final con-
firmation of the identification was done with the API 20E
system and sequencing of aroC. The two remaining isolates
were identified as Salmonella serovar Paratyphi A, and we
believe that these isolates were present as mixed cultures with
Salmonella serovar Typhi on initial isolation. This is supported
by the finding for one culture that contained organisms that
were both SPI-7 negative, typical of Salmonella serovar Para-
typhi A, and tviB positive, typical of Salmonella serovar Typhi
(Fig. 2, lane 17). These classifications were subsequently con-
firmed by sequencing of the aroC gene of each isolate, which
provided a genetic signature of the serovar (Fig. 3). Thus,
although these bacteria were responsible for invasive salmo-
nellosis in humans, they had been misclassified by standard
laboratory methods. Therefore, of the 2,222 Salmonella sero-
var Typhi isolates recovered, 12 (0.5%) were agglutination
negative for Vi on primary subculture. The reported rates of
occurrence of Vi-negative Salmonella serovar Typhi by year
are presented in Table 2.
FIG. 2. Multiplex PCR for detection of SPI-7 and tviB. The presence of the tviB gene in the viaB locus is shown by a band at about 0.8 kb, and
the absence of the SPI-7 region is shown by a band at about 1.5 kb. The aroC products are at 0.6 kb. Lanes: Vi-positive controls Ty2 (lane 1),
SARB63 (lane 16), and CT18 (lane 24); Vi-positive clinical isolates BL13807, BL15339, and BL13510 (lanes 2 to 4, respectively); Vi agglutination-
negative Salmonella isolates BL9282 (lane 5), BL14907 (lane 6), BL13843 (lane 7), BL9283 (lane 8), BL12035 (lane 9), BL3081 (lane 10), BA788
(lane 11), BL4426 (lane 12), BL6886 (lane 13), BL6397 (lane 14), BL6583 (lane 15), BL2934 (lane 22), BL13994 (lane 17), BL9737 (lane 18),
BL1838 (lane 20), and BL2580 (lane 21); Vi negative controls Salmonella serovar Paratyphi A BL11161 (lane 19) and SARB64 (lane 23).
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Multiplex PCR for ViaB and SPI-7. To test if the phenotyp-
ically Vi-negative Salmonella serovar Typhi strains encoded
the genes for Vi production, a multiplex PCR was developed to
detect either the presence of tviB within the actual ViaB (Vi
capsule biosynthesis)-coding region or the absence of the
whole 134-kbp SPI-7 sequence (Fig. 1). This PCR was used to
amplify all initial Salmonella isolates negative for Vi by agglu-
tination (12 Salmonella serovar Typhi isolates, 2 Salmonella
serovar Paratyphi A isolates, and 3 group D Salmonella iso-
lates). Three Salmonella serovar Typhi clinical isolates and
strains SARB63, CT18, and TY2, all freshly positive for Vi
agglutination, acted as positive controls. Salmonella serovar
Typhi SARB64 and three clinical isolates of Salmonella serovar
Paratyphi A served as negative controls. The presence of Sal-
monella DNA was confirmed by including Salmonella aroC-
specific primers in the multiplex PCR. All positive and nega-
tive controls routinely yielded the expected results: a PCR
product of 846 bp for Vi-positive isolates and a PCR product
of 1,275 bp, indicating the absence of SPI-7, for the negative
controls (Fig. 1 and 2). Of the 12 agglutination-negative Sal-
monella serovar Typhi isolates, 11 gave products of 846 bp,
indicating the presence of tviB (tviB), and 1 gave a product of
1,275 bp, suggesting that this organism did not harbor SPI-7.
The PCR results therefore show that 11 of 12 of the Vi agglu-
tination-negative Salmonella serovar Typhi isolates possessed
the tviA gene required for the synthesis and expression of the
Vi antigen. Significantly, over the 4-year period only one iso-
late of Salmonella serovar Typhi had lost the whole gene se-
quence for SPI-7, as shown by the presence of a product be-
tween the pheU and phoN (Fig. 4).
Subculture on medium with low osmolarity. There is evi-
dence that Vi expression is influenced by osmolarity and that it
is enhanced by the culture medium and conditions of low
osmolarity, e.g., those obtained with 0.17 M NaCl (26). At the
time of isolation, all of the Vi agglutination-negative Salmo-
nella serovar Typhi isolates were routinely subcultured onto
low-osmolarity LB agar (0.17 M NaCl; Difco, Detroit, Mich.).
However, none of these isolates became detectably Vi agglu-
tination positive following subculture. However, following stor-
age on Protect Beads (Prolabs, Poole, United Kingdom) for
various periods of several months to years at 70°C and sub-
sequent subculture on LB agar containing 0.17 M NaCl, 9 of 11
previously Vi agglutination-negative tviB isolates grew as cul-
tures that were positive for Vi by agglutination. Hence, the
FIG. 3. Sequence alignment of PCR product from the aroC gene of Vi agglutination-negative S. enterica. The sequences were compared to that
of aroC of strain CT18. Boxed nucleotides represent variations from the consensus sequence.
TABLE 2. Occurrence of Vi agglutination-negative Salmonella,
by year
Yr Total no.of isolates
No. (%) of Vi agglutination-
negative isolates
2002 565 6 (1.06)
2001 783 5 (0.06)
2000 321 4 (1.24)
1999 558 2 (0.358)
All yr 2,227 17a (0.76)
a Five of the isolates were later shown to be non-Salmonella serovar Typhi
salmonellae.
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storage conditions used apparently favored the generation of
Salmonella serovar Typhi capable of surface-associated Vi pro-
duction. Interestingly, there were still two Salmonella serovar
Typhi isolates which had the tviB gene but which could not be
shown to express Vi by agglutination after storage.
Immunofluorescence detection of Vi. Immunofluorescence
microscopy facilitates the direct detection of the Vi capsule on
individual Salmonella serovar Typhi bacteria and was found to
be a very sensitive method for the detection of Vi expression
(our results, not shown). All of the original 11 Vi agglutination-
negative Salmonella serovar Typhi isolates, which were positive
for both SPI-7 and tviB, were tested for Vi expression by
immunofluorescence microscopy with the same anti-Vi anti-
serum used for the agglutination tests. All were positive for Vi
production by comparison with known negative controls. In-
terestingly, this included the two Salmonella serovar Typhi
isolates that were negative by agglutination after storage (Fig.
5). The reason for this is likely to be the higher sensitivity of the
immunofluorescence microscopy technique compared with
that of agglutination.
Thus, of 17 Salmonella serovar Typhi isolates from clinical
specimens originally reported to be Vi negative, only 1 was
in fact a truly Vi-negative Salmonella serovar Typhi isolate.
Eleven cases of false negativity were caused by a false-
negative agglutination test result when the primary isolates
were tested. The results of all the investigations are sum-
marized in Table 3.
DISCUSSION
We show here that more than 99% (2,221 of 2,222) of
human blood isolates of Salmonella serovar Typhi in Pakistan
were able to express the Vi capsular antigen. There were orig-
inally 17 non-Vi-agglutinable isolates, of which 5 were shown
to be non-serovar Typhi Salmonella isolates. Of the remaining
12 isolates, 11 were shown to be capable of expressing Vi under
some conditions. The one truly Vi-negative Salmonella serovar
Typhi isolate had lost not only the viaB locus, which encodes
proteins associated with Vi biosynthesis, but the whole of
SPI-7, which contains other genes associated with virulence
(25). Given the unstable nature of this region of the Salmonella
serovar Typhi genome (27), we believe that this shows a re-
markably high degree of conservation of Vi expression in pri-
mary isolates when they are characterized prior to storage and
extensive laboratory passage. In contrast, reports from differ-
ent regions of India have described both a high prevalence (22)
and a low prevalence (14) of Vi-negative Salmonella serovar
Typhi isolates when serovar Typhi isolates were tested.
Given that the use of the capsular polysaccharide-based vac-
cines for protection against other pathogens, such as S. pneu-
moniae, has led to concern about an increase in the proportion
of strains expressing capsular types not incorporated into the
vaccine (8), the proportion of Vi-negative Salmonella serovar
Typhi isolates in natural bacterial populations potentially has
major implications for the use of Vi antigen-based typhoid
FIG. 4. Sequence alignment of PCR product across the pheU tRNA gene of Vi agglutination-negative S. enterica. The sequence from
Salmonella serovar Typhi CT18 with SPI-7 removed is presented for comparison. Boxed nucleotides represent variations from the consensus
sequence.
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vaccines (4, 12, 16). We therefore believe that it will be criti-
cally important to establish robust methods for the analysis of
Vi expression by Salmonella serovar Typhi in areas where Vi
vaccines are used and recommend a serological approach com-
bined with genetic analysis that incorporates PCR analysis.
Attempts to identify Vi-negative Salmonella serovar Typhi iso-
lates by purely agglutination-based approaches should be
viewed with caution. Vi expression by Salmonella serovar
Typhi has been shown to be subject to regulation involving
two-component sensors-regulators, RcsB-RcsC (2) and
OmpR-EnvZ (26), which respond to changes in environmental
conditions, such as osmolarity. Vi expression is thus complex
and is likely to be subject to regulation by other unknown
factors. It is possible that Salmonella serovar Typhi isolates
reported to be Vi agglutination negative from direct cultures in
clinical microbiology laboratories are actually Vi positive but
demonstrate a down regulation of Vi that could occur either in
the patient’s blood or during culture in the laboratory. Indeed,
we report this to be the case with nearly all (11 of 12) of the
Vi-negative isolates whose agglutination was determined in
this study.
Vi-negative Salmonella serovar Typhi isolates accumulate at
significant rates following laboratory passage of the organism,
and so to investigate this, we have systematically tested all
Salmonella serovar Typhi isolates recovered at the Aga Khan
laboratories in Karachi over a 4-year period (1999 to 2002) for
Vi expression using traditional microbiology identification
techniques and then screened the Vi-negative Salmonella se-
rovar Typhi isolates using specific immunofluorescence and
genetic characterization. During primary isolation, 0.5% (12 of
2,222) of the Salmonella serovar Typhi isolates were found to
be Vi agglutination negative. Eleven of these 12 Vi agglutina-
tion-negative isolates were positive for the tviB gene, which
suggested that the genetic machinery required for Vi expres-
sion was present. Although none of the 11 tviB isolates be-
came Vi agglutination positive after passage on low-osmolarity
agar at the time of isolation, 9 of them became positive after
they were frozen and recultured in low-osmolarity broth. This
illustrates the difficulties in attempting to determine the Vi
types of Salmonella serovar Typhi isolates purely by serological
methods. By immunofluorescence, all 11 isolates were shown
to be capable of expressing Vi after storage (Fig. 5). Of im-
portance to this study is that all of the Salmonella serovar
Typhi isolates which possessed tviB were able to express the Vi
antigen, as shown by immunofluorescence, suggesting that the
PCR used here for the detection of tviB has application for the
detection of Vi-negative Salmonella serovar Typhi on primary
culture. Further characterization of the relationship between
FIG. 5. Immunofluorescent staining of Vi agglutination-negative Salmonella serovar Typhi. Strain BL6397 is the Vi-positive control, and strain
BL11161 is the Vi-negative control. First column, bacteria labeled with anti-Salmonella antibody (green channel); second column, bacteria labeled
with anti-Vi antibody (red channel); third column, merged images of the first two columns. Original magnification, 1,000.
VOL. 43, 2005 Vi-NEGATIVE SALMONELLA SEROVAR TYPHI 1163
the presence of tviB and the expression of Vi is needed, how-
ever, as an IS1 insertion sequence is present in this region in
CT18, and the effects of this on Vi expression are unknown.
Although we (27) and others (23) have shown the presence of
SPI-7-negative Salmonella serovar Typhi strains in culture col-
lections, these may accumulate because of the culture or stor-
age conditions used. It is therefore important to test Salmo-
nella serovar Typhi isolates for the presence of the Vi genes on
primary isolation with as little subculturing as possible. It is
possible that the particular strains of Salmonella serovar Typhi
or the culture and isolation conditions used in Pakistan may
favor the retention of the SPI-7 island and that the conditions
and/or the strains encountered elsewhere may favor the loss of
SPI-7 or Vi expression. Thus, it will be important to perform
studies similar to ours in different geographical locations in
laboratories that use different isolation techniques.
The genetics of Vi are well understood. In addition to reg-
ulatory genes that influence the levels of Vi expression, 11
genes within the ViaB operon are involved in Vi biosynthesis
(9). Furthermore, ViaB is encoded on a potentially mobile
pathogenicity island, SPI-7, which contains 134 kbp of DNA
(Fig. 1). From sequence analysis it is predicted that SPI-7 is
capable of excision from the Salmonella serovar Typhi chro-
mosome (6, 27). The question remains whether the genes for
Vi expression could be lost under the potentially overwhelming
selective pressure against this capsule from Vi vaccination pro-
grams. The licensed parenteral typhoid vaccines are based on
purified Vi antigen alone, and new vaccines in which the an-
tibody response to this antigen is enhanced by conjugation of
the antigen to carrier proteins are being developed (19). These
vaccines will not provide protection against other Salmonella
serovars, such as Salmonella serovar Paratyphi and nontyphoi-
dal group D salmonellae, which may thus emerge as important
causes of systemic salmonellosis. Furthermore, live oral ty-
phoid vaccines which constitutively express Vi are also being
developed and may have similar effects (29). Vi-negative Sal-
monella serovar Typhi can become clinically important only if
the capsule is not essential for pathogenesis or transmission. At
present, the Vi antigen is considered important in the patho-
genesis of typhoid fever and possibly protects the bacterium
from complement-mediated killing and phagocytosis. How-
ever, Vi-negative Salmonella serovar Typhi can cause a typhoid
fever-like illness, as can Salmonella serovar Paratyphi A, which
does not typically express the Vi antigen (15). Our data suggest
that Vi may have a vital role in typhoid fever, but further study
of the molecular epidemiology of the bacteria which cause
invasive salmonellosis, particularly in regions where Vi vacci-
nation is extensive, is imperative. The multiplex PCR and im-
munofluorescence assay developed for this study should prove
invaluable for screening for Vi-negative Salmonella serovar
Typhi postvaccination.
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